To read the full story, subscribe or sign in.

Inmagene gains rights to Syk inhibitor fostamatinib in Chinese markets

Aug. 17, 2021

Inmagene Biopharmaceuticals Co. Ltd. has licensed rights from Kissei Pharmaceutical Co. Ltd. to develop and commercialize the spleen tyrosine kinase (Syk) inhibitor fostamatinib for all potential indications in China.

BioWorld Asia Deals and M&A Hematologic China

Today's news in brief

BioWorld

BioWorld briefs for March 17, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 17, 2022.

‘Biology no one else will have seen;’ startup Relation seeks new genetic targets

BioWorld

Newco Relation Therapeutics Ltd. is showing its colors after raising $25 million in a seed round to work on integrating single cell transcriptomics, functional...

Nasal spray Zavzpret cleared, Pfizer showing ‘growth on every measure’ in migraine

BioWorld

Pricing won’t be known until later for Pfizer Inc.’s Zavzpret (zavegepant), which became the first and only calcitonin gene-related peptide receptor antagonist...

Affibody in $637M respiratory disease deal with Chiesi

BioWorld

Chiesi Farmaceutici SpA has agreed to pay Affibody AB up to $214 million in a collaboration and licensing agreement to develop an inhaled treatment for...

Upgrade your daily dose of biopharma and medtech news

Inmagene gains rights to Syk inhibitor fostamatinib in Chinese markets